GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE1048.30-3.25 (-0.31 %)
PREV CLOSE ( ) 1051.55
OPEN PRICE ( ) 1020.20
BID PRICE (QTY) 1048.00 (23)
OFFER PRICE (QTY) 1050.00 (5)
VOLUME 21363
TODAY'S LOW / HIGH ( )1020.20 1060.15
52 WK LOW / HIGH ( )481.05 1068
NSE1044.00-7.8 (-0.74 %)
PREV CLOSE( ) 1051.80
OPEN PRICE ( ) 1031.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 585473
TODAY'S LOW / HIGH( ) 1031.00 1060.00
52 WK LOW / HIGH ( )487.15 1070
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 18-11 1977
Management Info
Glenn Saldanha - Chairman Glenn Saldanha - Managing Director
Registered Office

Address B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone

Email complianceofficer@glenmarkpharma.com

Website www.glenmarkpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
10Apr Glenmark Pharmaceuticals recalls 6,528
Glenmark Pharmaceuticals is recalling 6,528 bottles of Diltiazem Hydroch..
01Apr Glenmark Pharmaceuticals informs about
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
06Mar Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that it enclosed disclosure pursua..
19Feb Glenmark Pharmaceuticals informs about
Further to letter dated 2nd February, 2024 and pursuant to Regulation 30..
01Feb Infosys, Cochin Shipyard and Glenmark
Infosys has signed a seven-year strategic collaboration with Musgrave, I..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit-204.08999999999912087.69
Gross Profit -755.019999999999 15718.74
Operating Profit 745.47000000000124587.06
Net Sales 13650.9682206.62
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Neuland Laboratories (BSE)
 7127.00 (7.00%)
M.Cap (Rs. in Cr)9096.39
Bharat Parenterals (BSE)
 1390.00 (2.45%)
M.Cap (Rs. in Cr)768.20
Sanofi India (BSE)
 8512.00 (0.25%)
M.Cap (Rs. in Cr)19609.54
Glaxosmithkline Phar (BSE)
 1904.90 (1.11%)
M.Cap (Rs. in Cr)32218.49
SMS Lifesciences (BSE)
 685.25 (2.58%)
M.Cap (Rs. in Cr)210.87
Shareholding Pattern
PROMOTERS 46.65%
NON-INSTITUTION 18.69%
MUTUAL FUNDS/UTI 8.59%
FI/BANKS/INSURANCE 1.88%
GOVERNMENT 0.04%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.